Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) Restructuring Costs (2022 - 2024)

Historic Restructuring Costs for Krystal Biotech (KRYS) over the last 3 years, with Q3 2024 value amounting to $12.5 million.

  • Krystal Biotech's Restructuring Costs changed N/A to $12.5 million in Q3 2024 from the same period last year, while for Jun 2025 it was $12.5 million, marking a year-over-year decrease of 5000.0%. This contributed to the annual value of $37.5 million for FY2024, which is 20000.0% up from last year.
  • Krystal Biotech's Restructuring Costs amounted to $12.5 million in Q3 2024.
  • Krystal Biotech's 5-year Restructuring Costs high stood at $25.0 million for Q1 2022, and its period low was $12.5 million during Q1 2023.
  • For the 3-year period, Krystal Biotech's Restructuring Costs averaged around $15.0 million, with its median value being $12.5 million (2023).
  • In the last 5 years, Krystal Biotech's Restructuring Costs plummeted by 5000.0% in 2023 and then changed by 0.0% in 2024.
  • Over the past 3 years, Krystal Biotech's Restructuring Costs (Quarter) stood at $25.0 million in 2022, then tumbled by 50.0% to $12.5 million in 2023, then changed by 0.0% to $12.5 million in 2024.
  • Its Restructuring Costs stands at $12.5 million for Q3 2024, versus $12.5 million for Q2 2024 and $12.5 million for Q1 2024.